{"id":"albumin-treatment","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Albumin is a protein made by the liver that helps keep fluid in your bloodstream so it doesn't leak into other tissues. In albumin treatment, albumin is administered intravenously to patients with hypoalbuminemia, a condition characterized by low levels of albumin in the blood.","oneSentence":"Albumin treatment involves the administration of albumin to replace lost albumin in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:48.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypoalbuminemia"},{"name":"Severe burns"},{"name":"Severe liver disease"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT07493993","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-06-01","conditions":"ESCC","enrollment":26},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT06435546","phase":"NA","title":"Adherence to Oral Therapies in Advanced Breast and Prostate Cancers","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2024-06-04","conditions":"Breast Cancer, Prostate Cancer","enrollment":200},{"nctId":"NCT05685602","phase":"PHASE1","title":"CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-12","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8","enrollment":43},{"nctId":"NCT07415148","phase":"NA","title":"Hyaluronic Acid and Albumin-PRF in Non-Surgical Periodontal Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inonu University","startDate":"2025-04-09","conditions":"Periodontitis, Periodontal Inflammation","enrollment":51},{"nctId":"NCT05982522","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Solid Tumors","status":"WITHDRAWN","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-08-13","conditions":"Solid Tumor","enrollment":""},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8","enrollment":304},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":"Acute-on-Chronic Liver Failure (ACLF)","enrollment":56},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT02199145","phase":"NA","title":"Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-07-17","conditions":"Membranous Nephropathy","enrollment":52},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07348536","phase":"NA","title":"Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","status":"NOT_YET_RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2026-04","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease on Hemodialysis, Renal Dialysis","enrollment":15},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT07491445","phase":"PHASE3","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-03-09","conditions":"Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC","enrollment":900},{"nctId":"NCT07490002","phase":"PHASE2","title":"Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-04-06","conditions":"Esophageal Squamous Carcinoma","enrollment":33},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":"TNBC","enrollment":43},{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":387},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":176},{"nctId":"NCT06493019","phase":"PHASE2","title":"Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer","status":"RECRUITING","sponsor":"Dustin Deming","startDate":"2024-09-30","conditions":"Anal Cancer","enrollment":23},{"nctId":"NCT06643507","phase":"PHASE2, PHASE3","title":"Evaluation of the Modified VISTA Technique Using ALB-PRF vs CTG in the Treatment of Multiple Miller Class III Recessions","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-04-20","conditions":"Gingival Recession","enrollment":26},{"nctId":"NCT04894643","phase":"NA","title":"Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2020-09-14","conditions":"Pancreatic Cancer, Proton Therapy","enrollment":10},{"nctId":"NCT07483554","phase":"PHASE2","title":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-25","conditions":"CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":389},{"nctId":"NCT07394387","phase":"PHASE2","title":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-01","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":39},{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":"Intensive Care Patients, Intensive Care Unit Patients, Critical Illness","enrollment":10000},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT07479628","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-04-01","conditions":"Thymic Carcinoma","enrollment":31},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT06492915","phase":"PHASE2","title":"Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2024-08-13","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":42},{"nctId":"NCT07283705","phase":"PHASE2","title":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-18","conditions":"Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer","enrollment":60},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT05852691","phase":"PHASE2","title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-07-18","conditions":"Breast Cancer","enrollment":83},{"nctId":"NCT04165070","phase":"PHASE1, PHASE2","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":450},{"nctId":"NCT06767527","phase":"PHASE3","title":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-02-07","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":416},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07475234","phase":"PHASE1, PHASE2","title":"Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Xiuchao Wang","startDate":"2026-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT06525623","phase":"NA","title":"Initial Resuscitation for Acute Kidney Injury in Cirrhosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-09-12","conditions":"Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome","enrollment":50},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT05285358","phase":"PHASE1","title":"Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-09-19","conditions":"Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma","enrollment":12},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":"Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT03816163","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-03-15","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":393},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT06489015","phase":"EARLY_PHASE1","title":"Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Protgen Ltd","startDate":"2024-06-28","conditions":"Alzheimer's Disease (AD)","enrollment":30},{"nctId":"NCT07457528","phase":"PHASE2","title":"Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-12","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT06091345","phase":"NA","title":"Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-22","conditions":"Liver Cirrhosis","enrollment":61},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT06821503","phase":"PHASE1, PHASE2","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-11","conditions":"Advanced Pancreatic Cancer","enrollment":72},{"nctId":"NCT03028311","phase":"PHASE1","title":"Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-01-09","conditions":"Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer","enrollment":12},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07457359","phase":"PHASE2","title":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-04","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":18},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT06765590","phase":"NA","title":"Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-03-12","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT06646055","phase":"PHASE1, PHASE2","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2025-01-21","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":110},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT07452601","phase":"PHASE2","title":"Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT00616967","phase":"PHASE2","title":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-05","conditions":"Breast Cancer","enrollment":68},{"nctId":"NCT04002531","phase":"NA","title":"A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2018-11-10","conditions":"Quality of Life, Renal Insufficiency, Cardiac Event","enrollment":5},{"nctId":"NCT06953999","phase":"PHASE3","title":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-11","conditions":"Pancreatic Cancer","enrollment":999},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT07449364","phase":"NA","title":"Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient","status":"COMPLETED","sponsor":"Daewoong Group Indonesia","startDate":"2025-03-24","conditions":"Frailty in Older Adults","enrollment":10},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT07445295","phase":"PHASE3","title":"Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2026-03-31","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":558},{"nctId":"NCT07116330","phase":"","title":"Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2025-09-01","conditions":"Epilepsy, Seizure","enrollment":420},{"nctId":"NCT07444541","phase":"PHASE1, PHASE2","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anova Innovation Limited","startDate":"2026-03","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT03652428","phase":"PHASE1, PHASE2","title":"Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2019-04-02","conditions":"Locally Advanced Pancreatic Cancer","enrollment":24},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":"HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07435922","phase":"","title":"Evaluate Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment","status":"NOT_YET_RECRUITING","sponsor":"Healthgen Biotechnology Corp.","startDate":"2026-02-24","conditions":"Hypoalbuminemia, Hypovolemia","enrollment":2000},{"nctId":"NCT06103864","phase":"PHASE3","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-23","conditions":"Breast Cancer","enrollment":625},{"nctId":"NCT06608927","phase":"PHASE3","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2024-12-13","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":610},{"nctId":"NCT04104672","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2019-11-06","conditions":"Advanced Pancreatic Cancer","enrollment":196},{"nctId":"NCT07437898","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study","status":"RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2024-09-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT07436741","phase":"PHASE3","title":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02","conditions":"Pancreatic Cancer, Adult","enrollment":106},{"nctId":"NCT06745882","phase":"PHASE2","title":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-06-13","conditions":"Non-small Cell Lung Cancer","enrollment":318},{"nctId":"NCT06797375","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants","status":"COMPLETED","sponsor":"Rallybio","startDate":"2025-04-14","conditions":"Hematologic Diseases, Autoimmune Diseases","enrollment":16},{"nctId":"NCT07432594","phase":"PHASE2","title":"Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":82},{"nctId":"NCT06692738","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-18","conditions":"Non-small Cell Lung Cancer","enrollment":880}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":172,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Human Albumin Grifols 200 g/l, solution for infusion"],"phase":"phase_2","status":"active","brandName":"Albumin treatment","genericName":"Albumin treatment","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albumin treatment involves the administration of albumin to replace lost albumin in the body. Used for Hypoalbuminemia, Severe burns, Severe liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}